Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.05 USD
Change Today 0.00 / 0.00%
Volume 0.0
BJCT On Other Exchanges
Symbol
Exchange
OTC US
As of 8:10 PM 07/27/15 All times are local (Market data is delayed by at least 15 minutes).

bioject medical technologies (BJCT) Snapshot

Open
$0.05
Previous Close
$0.05
Day High
$0.05
Day Low
$0.05
52 Week High
10/13/14 - $0.35
52 Week Low
06/19/15 - $0.04
Market Cap
4.5M
Average Volume 10 Days
9.7K
EPS TTM
$0.01
Shares Outstanding
86.3M
EX-Date
--
P/E TM
5.2x
Dividend
--
Dividend Yield
--
Current Stock Chart for BIOJECT MEDICAL TECHNOLOGIES (BJCT)

Related News

No related news articles were found.

bioject medical technologies (BJCT) Related Businessweek News

No Related Businessweek News Found

bioject medical technologies (BJCT) Details

Bioject Medical Technologies Inc., together with its subsidiaries, develops, manufactures, and distributes needle-free injection therapy systems for the pharmaceutical and biotech industries in the United States. Its needle-free injection products include Biojector 2000 system that delivers intramuscular, subcutaneous, and intradermal injections; ZetaJet system, which provides vaccines and injectable medications either subcutaneously or intramuscularly for professional and home use; and a needle-free drug reconstitution system, which allows the transfer of diluents to reconstitute powdered medications into liquid form and withdrawal of liquid medication into a syringe without the use of a needle. It also offers a needle-free drug reconstitution vial adapter, a plastic device that replaces a fill needle for accessing medication vials making syringe filling completely needle-free. In addition, the company is developing Intradermal Pen spring-powered needle-free injector; Iject gas-powered and versatile injection systems; Jupiter Jet, a hand-held device for administering small volumes of drugs; and multi-port orifices for intradermal injections. Bioject Medical Technologies Inc. was founded in 1985 and is based in Tigard, Oregon.

bioject medical technologies (BJCT) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

bioject medical technologies (BJCT) Key Developments

Bioject Medical Technologies Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Bioject Medical Technologies Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported net sales of $314,000 compared to $341,000 a year ago. Operating loss was $253,000 compared to $260,000 a year ago. Net loss allocable to common shareholders was $327,000 or $0.01 per basic and diluted share compared to $316,000 or $0.02 per basic and diluted share a year ago.

Bioject Medical Technologies Inc. announced delayed 10-Q filing

On 05/15/2015, Bioject Medical Technologies Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.

Bioject Medical Technologies Inc. Reports Earnings Result for the Fourth Quarter and Year Ended December 31, 2014

Bioject Medical Technologies Inc. reported earnings result for the fourth quarter and year ended December 31, 2014. For the quarter, the company reported net loss allocable to common shareholders of $305,000, or $0.01 per diluted share compared to a net income allocable to common shareholders of $215,000, or $0.01 loss per diluted share, for the same quarter ended December 31, 2013. Net sales were $513,000 compared to $384,000 for the same quarter ended December 31, 2013. Operating loss was $250,000 compared with income of $268,000 a year ago. For the year, the company reported net loss allocable to common shareholders of $1,141,000 million, or $0.04 loss per share, compared to a net loss allocable to common shareholders of $1,133,000 or $0.06 loss per share, for the year ended December 31, 2013. Net sales were $1,825,000 compared to $1,530,000 for the year ended December 31, 2013. Operating loss was $907,000 compared with $969,000 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BJCT:US $0.05 USD 0.00

BJCT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Antares Pharma Inc $2.06 USD +0.06
Becton Dickinson and Co $148.99 USD +2.66
Ypsomed Holding AG SFr.106.60 CHF -0.70
View Industry Companies
 

Industry Analysis

BJCT

Industry Average

Valuation BJCT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.1x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOJECT MEDICAL TECHNOLOGIES, please visit www.bioject.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.